A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system

Background: Apalutamide is a new drug class, which is approved to treat prostate cancer (PCa). The aim of our study was to assess the safety profiles of apalutamide in real-world through data mining of the United States Food and Drug Administration Adverse Event Reporting System (FAERS).Method: We i...

Full description

Bibliographic Details
Main Authors: Zhihong Fang, Zhiqiang Xu, Wei Zhu, Mingming Yu, Chunmei Ji
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pharmacology
Subjects:
apalutamide
FDA adverse event reporting system
disproportionality analyses
adverse event
real-world
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1101861/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1101861/full

Similar Items